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Vaginal yeast infections are among the most common reasons for women seeking
medical care; it has been estimated that 70–75 % of women have an episode of Candida
vaginitis at least once during their lifetime (1). Local administration of antimicrobial
agents has been favored in the treatment of vaginitis because of the numerous side ef-
fects of systemically applied drugs. Vaginal dosage forms used for this purpose include
solutions, gels, creams, ointments, foams, pessaries, tablets and vaginal inserts (1). To
achieve a desirable therapeutic effect, vaginal delivery systems need to have the ability
to spread onto the vaginal mucosa surface and guarantee an intimate and prolonged
contact at the site of application (2). Therefore, localized mucoadhesive dosage forms
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The aim of the present study was to evaluate chitosan as
a vaginal mucoadhesive gel base for econazole nitrate and
miconazole nitrate. To this aim, different types of chitosan
with different molecular masses and viscosity properties
[low molecular mass chitosan (viscosity: 20,000 mPa s),
medium molecular mass chitosan (viscosity: 200,000 mPa s),
high molecular mass chitosan (viscosity: 800,000 mPa s)]
have been used. First, rheological studies were conduct-
ed on chitosan gels. Mechanical, syringeability and mu-
coadhesive properties of chitosan gels were determined.
Release profiles of econazole nitrate and miconazole ni-
trate from chitosan gels were obtained and evaluated kine-
tically. In addition, anticandidal activities of formulations
were determined. Finally, vaginal retention of chitosan
gels in rats was evaluated by in vivo distribution studies.
Based on the results, it can be concluded that gels pre-
pared with medium molecular mass chitosan might be
effectively used for different antifungal agents in the treat-
ment of vaginal candidiosis, since it has high mucoadhe-
siveness, suitable mechanical and release properties with
good vaginal retention.
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may be regarded as a suitable formulation design to improve both the bioavailability of
the drug and patient compliance while traditional vaginal preparations might not en-
sure satisfactory therapy.
Mucoadhesive gels have a high capability of adhering to mucosal surfaces, which
cover various body cavities such as the vagina and prolong the residence time of the
drug delivery system at the application site and decrease the number of applications re-
quired (3). Use of natural polymers is valuable for the preparation of mucoadhesive gel
formulations owing to their proven biocompatibility and safety. In this respect, the poly-
saccharide chitosan has received particular attention over the past 20 years (4). Chitosan
is a natural copolymer consisting of glucosamine and N-acetylglucosamine units. It has
a cationic character based on its primary amino groups. These primary amino groups of
chitosan are responsible for various properties (i.e., controlled drug release, mucoadhe-
sion, in situ gelation and permeation enhancement). In addition, chitosan and its deriva-
tives have efflux pump inhibitory properties. They are able to reversibly inhibit efflux
pumps and owing to this property the mucosal uptake of various efflux pump substrates
(such as anticancer drugs, antimycotic drugs and antiinflammatory drugs) can be great-
ly improved (4). All of these properties make chitosan an ideal candidate for being used
in drug delivery systems (4, 5).
Miconazole nitrate (MN) and econazole nitrate (EN) are imidazole derivative anti-
fungal drugs used to treat topical fungal and yeast infections (6). The objective of this
study was to comprehensively evaluate chitosan as a vaginal gel base for EN and MN.
For this purpose, different types of chitosan with different molecular masses and viscos-
ity properties have been used for the preparation of mucoadhesive gels. First of all, a
comprehensive rheological study was conducted on prepared chitosan gels. Mechanical,
syringeability and mucoadhesion properties of chitosan gels were determined with a
TA-XT Texture Analyzer (7). Release profiles of MN and EN were obtained and evalu-
ated kinetically. In addition, anticandidal activities of formulations were determined by
the agar well diffusion method. Finally, the vaginal retention of chitosan gels in rats was
evaluated by in vivo distribution studies.
EXPERIMENTAL
Materials
Low molecular mass chitosan [Brookfield viscosity (1 %, m/V, in 1 % acetic acid so-
lution at 25 °C): 20,000 mPa s, 75–85 % deacetylated], medium molecular mass chitosan
[Brookfield viscosity (1 %, m/V, in 1 % acetic acid solution at 25 °C): 200,000 mPa s, 75–85
% deacetylated], high molecular mass chitosan [Brookfield viscosity (1 %, m/V, in 1 %
acetic acid solution at 25 °C): 800,000 mPa s, > 75 % deacetylated] and EN were pur-
chased from Sigma-Aldrich (GERMANY). MN was obtained from ÝLSAN-ÝLTAÞ Phar-
maceutical Company (TURKEY). All other materials were of analytical grade.
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Preparation of formulations
Gel formulations were prepared using chitosan of three different molecular masses.
Briefly, chitosan of 2 % (m/m) concentration was dissolved in diluted lactic acid solution
(1 %, V/V). Percent chitosan concentration was chosen according to literature findings
and preformulation studies (8). Chitosan concentration in gel formulations was kept
constant to evaluate the difference between chitosan types. MN or EN was incorporated
into formulations at 2 % (m/m) and 1 % (m/m) concentrations, respectively. MN and EN
concentrations were chosen in accordance with their concentration in commercial prod-
ucts. Compositions of gels are given below:
F1: Formulations prepared with low molecular mass chitosan (2 %)
F2: Formulations prepared with medium molecular mass chitosan (2 %)
F3: Formulations prepared with high molecular mass chitosan (2 %).
Determination of pH
The pH values of gels were measured with a pH-meter (WTW series pH 720) at room
temperature. The pH values of formulations were checked 24 hours upon preparation.
Rheological studies
Rheological analysis of chitosan gels was performed at 37 ± 0.1 °C with a Haake
Mars rheometer (Thermo Fisher, Germany). Analysis was performed in flow mode and
in conjunction with parallel steel plate geometry (40 mm diameter) with a gap of 0.3
mm, as described previously (9). In continuous shear analysis, the upward and down-
ward flow curves for each formulation were measured over shear rates (10–2000 s–1).
Oscillatory analysis of each formulation was performed after determination of its
linear viscoelastic region at 37 ± 0.1 °C, where stress was directly proportional to strain
and the storage modulus remained constant. Frequency sweep analysis was performed
over the frequency range of 0.1–10.0 Hz following application of a constant stress. The
standard gap size was 0.3 mm for each sample. Storage modulus (G') and loss modulus
(G“) of the formulations were determined as previously described (10). In each case, rhe-
ological properties of the formulations were examined at least six times.
Mechanical properties of formulations
Textural analysis was performed to determine mechanical properties of the formu-
lations using a software-controlled penetrometer (TA-TX Plus, Stable Micro System, UK)
equipped with a 5 kg load cell. Formulations were initially transferred into glass vials
(20 mL). An analytical probe was twice compressed into each formulation to a defined
depth (15 mm) and at a defined rate (2 mm s–1), allowing a delay period (15 s) between
the end of the first and beginning of the second compression. Experiments were carried
out at least six times. As a result of this study, a force-time curve was obtained (Fig. 1)
and mechanical parameters (hardness, compressibility, adhesiveness, cohesiveness and
elasticity) were calculated (11).
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Hardness is the force required to attain a given deformation and the altitude of the
first peak gives the hardness value. Compressibility is the work required to deform the
product during the first compression of the probe and the first area under the curve
(AUC) defines compressibility. Adhesiveness is the work necessary to overcome the at-
tractive forces between the surface of the sample and the surface of the probe. The sec-
ond AUC defines adhesiveness. Cohesiveness is the ratio of the area under the force-
-time curve produced in the second compression cycle to that in the first compression
cycle. Elasticity is the rate at which the deformed sample returns to its undeformed con-
dition after the removal of the deforming force. Cohesiveness and elasticity values were
calculated according to the following equations:
Cohesiveness = AUC3/AUC1 (1)
Elasticity = Time difference 3–4/Time difference 1–2 (2)
Syringeability of formulations
The work required to expel formulations from a syringe without a needle was mea-
sured using a TA-XT Texture Analyzer (Stable Micro Systems) in compression mode, as
previously described in literature (12). Shortly, formulations were packed into 2 mL
plastic syringes without needles to a height of 25 mm, avoiding air bubbles. The syringe
was then placed in the metallic support and immobilized with a plastic clamping ring. A
force transducer was connected to the texture analyzer TA-XT to measure the force with
which the arm of the texture analyzer moved and pushed the plunger of the syringe.
The probe was lowered at a constant speed (2.0 mm s–1) over a distance of 30 mm. The
resistance to expression of syringe contents (work done) was determined from the area
under the force-time curve recorded during plunger compression. All measurements were
performed in at least six replicates (12).
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Fig. 1. Schematic representation of the force-time curve obtained from textural analysis.
Mucoadhesion studies
Mucoadhesion measurements were performed using a TA-XT Texture Analyzer
(Stable Micro Systems) equipped with a load cell of 1 kg. A/MUC measuring system
(mucoadhesion test ring) consisting of a ring in which the biological support can be
fixed and a cylinder probe with a diameter of 1 cm were used. In this study, mucin dis-
persion (mucin from porcine stomach, Type II, Sigma-Aldrich, Germany) was used in-
stead of a biological support. A filter paper disc was wetted with 10 mL of mucin disper-
sion in phosphate buffer (8 %, m/m, pH 6.4). 20 mg of each sample was applied to the
cylinder probe. The sample and biologic substrate were put in contact with a preload of
6000 mN for 3 min. The cylinder probe was moved upwards at a predetermined speed
of 2.5 mm min–1 to separate the mucoadhesive interface (mucin-sample). The maximum
detachment force, as a function of displacement, was recorded and the work of adhesion
parameter (mN mm) was calculated as the area under the force vs. displacement curve.
The test was conducted at 37 °C and each experiment was carried out six times (13).
Release studies
The in vitro release studies of MN and EN from different chitosan gel bases were
carried out using Spectra/Por Regenerated Cellulose Dialysis Membrane Tubes
(12.000–14.000 MWCO). Membranes were soaked in distilled water for 24 hours before
the experiment. Phosphate buffer (pH 4.5) with dioxane (65:35, V/V) was used as recep-
tor medium (14). Each formulation was packed in dialysis bags, which were placed in
150 mL of buffer at 37 °C in sealed glass vials. The receptor medium was continuously
stirred. At certain time intervals, samples were withdrawn and the drug content of each
sample was analyzed spectrophotometrically (Shimadzu UV-Vis 1208 spectrophotomet-
er). Samples were measured at 273 nm and 270 nm for MN and EN contents, respec-
tively. All the experiments were repeated at least three times.
Determination of release mechanism
The release mechanism from gels was investigated using the Ritger-Peppas equa-
tion (15, 16).
Mt/M¥ = k tn (3)
In this equation; Mt is the drug released at time t, M¥ is the quantity of drug released at
infinite time, Mt/M¥ is fractional release, k is the diffusional constant and n is the
diffusional exponent that characterizes the drug release mechanism.
Determination of anticandidal activities of formulations
Anticandidal activities of formulations were determined by the agar well diffusion
method. The standard Candida albicans ATCC 90028 strain was inoculated onto a
Sabouraud Dextrose Agar (SDA, Oxoid) plate and incubated at 35 °C for 48 hours. A
suspension equal to the 0.5 McFarland turbidity standard was prepared in a sterile sa-
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line solution (8.5 g L–1) from the candida colonies. 100 µL of the suspension containing
approximately 1 × 106 – 5 × 106 colony forming units (CFU)/mL was spread on the
plates with a sterile swab and allowed to dry at room temperature for 5 minutes. Then,
20 mm diameter wells were made in the centers of SDA plates with a sterile scalpel. 0.5
mL of formulation with or without MN and EN was put into the wells aseptically. After
incubation for 24–48 hours at 35 °C, inhibition zone diameters formed around the for-
mulations were measured. To control the possible contamination of formulations, they
were placed on SDA plates that were not inoculated with C. albicans and incubated (17).
In vivo distribution studies
For in vivo distribution studies, the near-infrared dye IRDye 800RS Carboxylate
(LI-COR Biosciences, NE) was loaded in chitosan gels (10 mg/10 g, m/m). Female Wistar
albino rats (200–250 g) were anesthetized with ketamine. Vaginal and abdominal regions
of the rats were shaved and 0.2 mL of gels was given intravaginally using a syringe
without a needle. Rats were transferred to the MousePOD™ Adapter (model 9201-MP)
scanning surface of an Odyssey Infrared Imaging System (model 9201-3; LI-COR Biosci-
ences, USA). The MousePOD™ adapter was equipped with temperature regulators to
maintain animal temperature during scanning. Vaginal regions of animals were scanned
from tail to abdomen in two infrared channels simultaneously (700 and 800 nm), where
one channel (700 nm channel) was used for normalization of the measured infrared in-
tensities. The rats were scanned every hour for 8 h and 24 h after administration. The in-
tensities were displayed in pseudo colors by the Odyssey software (LI-COR Biosciences)
to isolate regions of interest (18). This in vivo study was performed following institu-
tional approval from the Ethics Committee of Adnan Menderes University (Aydýn, Tur-
key, No: B.30.2.ADU.0.00.00.00/050.04/2012/107). Experiments were carried out in ac-
cordance with the guidelines laid down by the Helsinki Declaration regarding the care
and use of animals for experimental procedures and in accordance with local laws and
regulations.
Statistical data analysis
Statistical data analysis was performed using the Student t-test with p < 0.05 as the
minimal level of significance.
RESULTS AND DISCUSSION
Results of pH measurements
The vaginal pH of healthy women of reproductive age is acidic (4.5–5.5). It is main-
tained by Lactobacilli present in the healthy vagina that play an important role in the
control of infection by common pathogens. These organisms also produce other bacteri-
cidal compounds such as hydrogen peroxide, bacteriocin-like substances and possibly
biosurfactants (19). The pH of formulations is one of important parameters for vaginal
compatibility. Therefore, the pH values of chitosan gels were determined first in this
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study. The results showed that all the formulations were suitable for vaginal application
as they could maintain the acidic pH value of the vagina (Table I). It was also observed
that the pH value of the gels did not change significantly when using different types of
chitosan. Addition of EN and MN into gel formulations significantly decreased pH val-
ues in all formulations (p < 0.05).
Results of rheological studies
Rheological properties affect the in vivo behavior of formulations in the vagina such
as application, spreadability and retention time. Spreadability of gels increased with a
decrease in viscosity. Also, the retention time of chitosan gels was affected by their vis-
cosity and rheological behavior. Therefore, were evaluated the rheological behavior of
chitosan gels and determined if the flow types of the formulations were Newtonian or
non-Newtonian.
It can be seen from Fig. 2 that the gels exhibited flow behavior in dependence on the
chitosan type. F1 formulation showed Newtonian flow due to its low viscosity. This flow
behavior is common in diluted gel and emulsion formulations. The reason for Newto-
nian flow behavior is that the molecules or micelles of this formulation did not get en-
tangled. Further, the formulation did not undergo a phase change to turn into a gel and
was still an easily flowing liquid, similar to pure water displaying typical Newtonian
flow behavior (20, 21). Solutions began to flow after shear stress reached its yield point.
Therefore, the flow curve for these solutions, under physiological conditions, exhibited
pseudoplastic behavior with hysteresis. The hysteresis phenomenon indicated the pres-
ence of an elastic component. Thus, strong gels formed with these polymers can be chara-
cterized as viscoelastic materials. Viscoelastic materials normally show hysteresis under
cyclic deformation. Viscoelastic materials are preferable to viscous materials because
they flow more easily and are less susceptible to deformation due to stress (21). On the
other hand, F2 and F3 formulations exhibited plastic flow. Plastics are shear thinning,
their curve begins with a yield value and their viscosity decreases with an increase in
shear rate (20, 21). It is clear that the type of chitosan affects the flow behavior of a for-
mulation.
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Table I. pH values of formulations
Formulation code pH ± SD
F1 5.34 ± 0.04
F2 5.44 ± 0.06
F3 4.98 ± 0.03
F1 + MN 4.82 ± 0.07
F2 + MN 4.67 ± 0.08
F3 + MN 4.53 ± 0.04
F1 + EN 3.85 ± 0.06
F2 + EN 3.92 ± 0.09
F3 + EN 3.79 ± 0.07
Oscillatory studies determine the viscoelastic property of the formulation by sub-
jecting the sample to sinusoidal shear stress. The effects of chitosan type and addition of
an active substance on the viscoelastic properties, namely, storage modulus (G', a mea-
sure of elasticity) and loss modulus (G“, viscous components) of the formulations, are
displayed in Fig. 3. As can be seen, these chitosan gels are characterized by lower G' and
higher G“ values, pointing to a mainly viscous polymer solution containing a network
established by physical entanglements. Also, at all frequency values a liquid-like behav-
ior is observed, so the viscous properties are more pronounced than the elastic ones (22).
Similar liquid type behavior has been reported for chitosan gels in the literature (22–24).
Results of our rheological studies also showed that the addition of MN or EN had no
significant effect on the flow behavior or viscosity values for all formulations (p > 0.05).
Mechanical properties of formulations
Vaginal semi-solid formulations should have appropriate mechanical properties
(e.g., mucoadhesive properties, ease of application, low hardness, and good retention at
the application site) to provide maximum benefit of the formulation to the patient (12).
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Fig. 2. Flow curves of chitosan gels.
Therefore, vaginal bioadhesive gel formulations were evaluated according to their me-
chanical properties and the results are given in Table II.
Adhesiveness is the work required to detach the probe from the sample and is re-
lated to bioadhesion. Cohesiveness provides information on the effects of repeated
shearing stresses on the structural properties of formulations. Hardness expresses the
applicability of the gel to the desired site. Compressibility determines the extraction of
the gel from the container and the simplicity of its spreadability on the application site.
Elasticity represents the rate at which the deformed sample returns to its undeformed
condition. Lower numerical values as determined by the Texture Profile Analysis (TPA)
in elasticity mode indicate higher product elasticity (11). Formulations should have
good adhesiveness properties to remain on the vaginal mucosa for a long period of time
and thereby decrease application frequency. On the other hand, compressibility and
hardness values of the formulations should be low to facilitate product removal from the
container and provide product comfort within the vaginal cavity.
As can be seen from Table II, increase in chitosan molecular mass and viscosity al-
tered the mechanical properties of all formulations. Formulations prepared with high
molecular mass hitosan exhibited the highest adhesiveness values. On the other hand,
the hardness and compressibility values of these formulations were, as expected, higher
than the others, which might be disadvantageous for their spreadibility on the vagina
and patient compliance. Hardness and compressibility of formulations prepared with
low molecular mass chitosan are low compared to other formulations. Nevertheless,
their adhesiveness is comparatively low, which might cause leakage during the use of
the formulation and restrict patient compliance.
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Fig. 3. Effects of chitosan type and addition of an active substance on storage modulus (G') and
loss modulus (G“).
Briefly, the compressibility and hardness values of formulations should be low
while adhesiveness and cohesiveness values should be high. Also, formulations should
show lower numerical values of elasticity, which indicate higher product elasticity.
Based on the results of mechanical properties, gels prepared with medium molecular
mass chitosan appeared to offer more suitable mechanical properties than gels for vagi-
nal application prepared with low and high molecular mass chitosan.
In addition, the results showed that the addition of active substances in 1 or 2 %
concentrations did not significantly affect the adhesiveness, cohesiveness, hardness,
compressibility and elasticity of the formulations.
Results of syringeability studies
The work required to expel samples from a syringe is another important parameter
for practical administration of gels with a syringe. This parameter shows the force re-
quired for the application of a formulation and affects clinical practice. Previously, Jones
et al., reported that increased product viscoelasticity (particularly elasticity) offered in-
creased resistance to product deformation in TPA. In syringeability analysis, this situa-
tion causes an increase in work required for compression/expulsion of the formulation
(25). Our results on elasticity, hardness and syringeability were in accord with this study
and the ranking was: F3 > F2 > F1 (Table II). In addition, significant increases in syring-
ing work were observed as the molecular weight and viscosity of chitosan increased (p <
0.05). F3 required most work to expel the liquid formulation from the syringe (or appli-
cator), which might be disadvantageous for the ease of administering formulations with
a syringe or applicator. In addition, the results showed that incorporation of 2 % MN or
1 % EN into chitosan gels had no significant effect on work required to expel formula-
tions from the syringe.
Results of mucoadhesion studies
Mucoadhesive properties of formulations play an important role in prolonging the
residence time and mucoadhesion should be determined sensitively. A TA-XTplus tex-
ture analyzer can be used to measure mucoadhesion of formulations under simulated
vaginal conditions, based on the principle of applying tensile strength and shear stress
to break the adhesive bond between the test sample and a model membrane (26). There-
fore, the mucoadhesive properties of chitosan gels were determined with a TA-XTplus
texture analyzer equipped with the A/MUC measuring system.
The results of mucoadhesion studies are presented in Table II. Chitosan is a
well-known bioadhesive polysaccharide and its mucoadhesive properties are likely to
be based on its cationic character. The mucus layer exhibits anionic structures in sialic
acid and sulfonic acid form. Based on ionic interactions between the cationic primary
amino groups of chitosan and these anionic substructures of the mucus, mucoadhesion
can be achieved. In addition, hydrophobic interactions might contribute to chitosan
mucoadhesive properties (4).
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Results of mucoadhesion studies were in accord with adhesiveness results obtained
from the texture profile analysis of formulations. Significant increases in the work of
mucoadhesion were observed as the molecular weight and viscosity of chitosan in-
creased (p < 0.05) and F3 showed stronger mucoadhesiveness than other formulations.
Results of release studies
The in vitro release profiles of MN and EN were evaluated in pH 4.5 phosphate
buffer at 37 °C and the results are displayed in Fig. 4. As can be seen, the release of EN
and MN were in range of 50–70 % over 8 hours. In 24 hours, the release rates of MN
from F1, F2 and F3 reached 89, 91 and 96 %, respectively. In addition, at the end of 24
hours, the release rates of EN from F1, F2 and F3 were 71, 67, 78 %, respectively (data
not shown).
Previous studies had shown that drug release might be influenced by gel viscosity.
As the viscosity of the gel increased, the release of the drug was expected to be slower.
(27). On the other hand, our results showed that the release profiles of MN and EN were
not significantly affected by the viscosity of chitosan (p > 0.05). When we compared the
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release rates of EN and MN from the same chitosan formulations, we found that the re-
lease rates of MN from F2 and F3 formulations were significantly higher than the release
rates of EN from F2 and F3 (p < 0.05). On the basis of release studies, it can be concluded
that F1, F2 and F3 formulations offer the advantage of controlling both MN and EN re-
lease over 8 hours.
Determination of the release mechanism
An empirical equation (Eq. 3), proposed by Ritger and Peppas, was used for the
analysis of release data in gel formulations (16). Application of the general release equa-
tion enabled calculation of n and hence identification of the mechanism of release from
the formulations. To this aim, the release data were fitted to Eq. 1, and best-fit parame-
ters were calculated. According to this equation, n = 0.5 indicates case I (Fickian) diffu-
sion or square root of time kinetics, 0.5 < n < 1.0 indicates anomalous (non-Fickian) dif-
fusion, n = 1.0 indicates case II transport, and n > 1.0 indicates super case II transport for
thin film formulations (28).
The values of diffusional exponents n, release rate constants k and correlation coeffi-
cients R2 are listed in Table III. The release exponents n of all formulations ranged from
0.288 to 0.470, which indicates case I (Fickian) drug release. In this case, diffusion of
drug molecules is the controlling mechanism of drug release.
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Fig. 4. Dissolution profiles of: a) MN and b) EN from chitosan gels in pH 4.5 phosphate buffer.
Results of determination of anticandidal activities of formulations
Chitosan and its derivatives have a spectrum of antimicrobial activity against fila-
mentous fungi, yeasts, Gram-positive and Gram-negative bacteria. Although chitosan is
not primarily used as an antimicrobial agent, its utility as an ingredient in pharmaceuti-
cal formulations and food has lately gained more interest (29). Therefore, the antican-
didal activity of chitosan gels against the standard Candida albicans ATCC 90028 strain
was evaluated and the results are given in Table IV.
Although chitosan was known to have anticandidal action against Candida albicans,
our results showed that F1, F2 and F3 formulations without MN or EN did not exhibit
any antimicrobial activity. Chitosan’s in vitro antimicrobial activity is influenced by vari-
ous intrinsic and extrinsic factors, such as chitosan itself (type, molecular mass, deace-
tylation degree, solvent and concentration) and the environmental conditions (test strain,
its physiological state and the bacterial culture medium, pH, temperature, ionic strength,
metal ions, EDTA, organic matter) (30). Therefore, we might conclude that our formula-
tions did not show antimicrobial activity due to some of these intrinsic or extrinsic pa-
rameters. It was stated in recent years that the antimicrobial properties of chitosan might
have a negative impact on healthy vaginal microflora and that its vaginal use for treat-
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F1 + MN 0.470 1.310 0.996
F2 + MN 0.412 1.440 0.985
F3 + MN 0.406 1.479 0.973
F1 + EN 0.349 1.400 0.982
F2 + EN 0.365 1.388 0.958
F3 + EN 0.288 1.510 0.991
Table VI. Inhibition zone diameters of formulations




F1 + MN 33.6 ± 1.5
F2 + MN 26.3 ± 0.5
F3 + MN 28.3 ± 0.5
F1 + EN 31 ± 1
F2 + EN 30.3 ± 1.5
F3 + EN 30.0 ± 2
ment of chronic diseases requires caution (4). From this point of view, we might say that
the absence of antimicrobial effect in our formulations without active substances might
be an advantageous outcome.
Chitosan gels with active substances showed anticandidal activity with inhibition
diameters between 26–34 mm. There were no significant differences in this anticandidal
activity among the formulations and active substances.
Results of in vivo distribution studies
Vaginal retention of gels is an important parameter to be evaluated in order to achie-
ve efficacy. Optimally, a mucoadhesive vaginal gel must be distributed over the mucosa,
maintaining an epithelial coating layer (31). To date, several in vitro and in vivo methods
have been developed and used to evaluate the distribution and retention of formulati-
ons in the vagina (31, 32). Imaging studies such as magnetic resonance imaging and
gamma scintigraphy still remain the most reliable methods for in vivo assessment of vag-
152
Z. A. Þenyiðit et al.: Evaluation of chitosan based vaginal bioadhesive gel formulations for antifungal drugs, Acta Pharm. 64 (2014)
139–156.
Fig. 5. Vaginal retention of formulations.
inal distribution and retention (33). In our study, we evaluated vaginal retention using a
new imaging method: Odyssey Infrared Imaging System with MousePOD™ adapter
(LI-COR Biosciences). The benefit of this method is that live animals are used and that
they are not exposed to radiation like in radio-imaging studies (34). Near-infrared im-
ages of rats administered RDye 800RS Carboxylate dye (peak absorption at 786 nm)
loaded chitosan gels are shown in Fig. 5.
The in vivo distribution studies showed that F1, F2 and F3 formulations remained in
the vaginal mucosa 24 h after application. It was stated in previous studies that the rhe-
ology of vaginal gel could be considered as one of the most important factors affecting
gel distribution and retention time in the vagina (35). Selection of correct viscosity of a
gel can be decisive for its adequate retention and distribution in the vagina. On the other
hand, our results showed that F1, F2 and F3 formulations with different chitosan viscos-
ity values remained on the vaginal mucosa up to 24 hours and no significant difference
was found among the formulations.
Previously, Di Fabio et al. evaluated the potential effectiveness of microbicides on
vaginal HIV-1 transmission formulated with two different polymers (carbopol and hyd-
roxyethylcellulose). The results showed that it was essential to achieve a uniform distri-
bution on vaginal mucosa in order to form an effective barrier. However, the gel with a
high viscosity value was difficult to apply and distribute on the vagina of mice. Then,
polymers with lower viscosity were examined to achieve a uniform distribution over the
entire vagina/cervix and the results showed that vaginal transmission of HIV was suc-
cessfully prevented by the application of this formulation (36). On the other hand, gels
with low viscosity values may result in leakage of the administered formulation from
the vagina and restrict the efficacy of the formulation or patient compliance. Therefore,
although no significant difference in vaginal retention time was noticed between the for-
mulations, F2 seems to be more suitable than F1 and F3 considering the mechanical,
mucoadhesive and syringeability properties. Anyway, in further in vivo studies, the dif-
ference between the formulations should be evaluated in more detail.
CONCLUSIONS
The aim of this study was the evaluation of chitosan (different molecular mass and
viscosity values) for the preparation of mucoadhesive vaginal gels. For this purpose,
miconazole nitrate and econazole nitrate were chosen as imidazole derivative active
substances. The gels were first comprehensively evaluated in in vitro characterization
studies (rheological evaluation, texture profile analysis, mucoadhesion, syringeability
and release studies). In addition, vaginal retention of the gels was investigated in vivo
through a distribution study on rats. Based on the results obtained from these studies, it
can be concluded that vaginal gels prepared with medium molecular mass chitosan
might be effectively used for different antifungal agents for the treatment of vaginal can-
didiasis, since they have high mucoadhesiveness, suitable mechanical and release prop-
erties with good retention in the vagina.
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